Targeted treatments for lupus still have a long way to go, but some studies are starting to pinpoint potential treatment pathways.
10 Clinical Insights & Rheumatology Pearls Presented at ACR Convergence 2021
Practical tips for the diagnosis, evaluation and treatment of a spectrum of conditions commonly encountered in a rheumatology practice are offered.
Experts Discuss Blood Disorders Commonly Seen in Lupus Patients
ACR CONVERGENCE 2021—Hematologic abnormalities are common in systemic lupus erythematosus (SLE), whether due to SLE itself or something else. As rheumatology professionals, we are routinely challenged by the management of cytopenias in our SLE patients. At the ACR’s annual meeting in 2021, two hematologists shared expert advice regarding common hematologic manifestations of SLE. Michael B….
Business Rheum: What to Expect from New MVP Measures
The new rheumatology-specific Merit-Based Incentive Payment System Value Pathway will focus on measures that most rheumatologists already track. The model should streamline reporting and better target quality improvements.
The ACR Thanks 2021 RheumPAC Matching Campaign Donors
With a record-high 46 first-time contributors, this year’s matching campaign raised more than $26,000 from members and another $17,000 from volunteer leaders who made a pledge for each donor, advancing advocacy efforts on behalf of rheumatology.
Advances in Connective Tissue Disease-Associated Interstitial Lung Disease
ACR Convergence 2021—The past year has been an exciting time for researchers and clinicians focused on the topic of connective tissue disease-associated interstitial lung disease (CTD-ILD), with advances in our understanding of these disorders and newly approved medications for their treatment. At the ACR Convergence 2021 annual Review Course, Kristin Highland, MD, MSCR, director of…
FDA Discussed 2021 Drug Warnings & Approvals at ACR Annual Meeting
ACR Convergence 2021—The recent Boxed Warning requirement applied to three Janus kinase (JAK) inhibitors, cautioning doctors and patients about several major risks in patients with rheumatoid arthritis, came only after rigorous data collection and careful consideration of the risks and the benefits, U.S. Food & Drug Administration (FDA) officials said in November at ACR Convergence…
Using the 2019 EULAR/ACR Classification Criteria to Predict Disease Severity in SLE
Predicting a patient’s disease course is difficult, especially in SLE. A recent study examined the link between a patient’s 2019 EULAR/ACR SLE Classification Criteria score at diagnosis to subsequent disease severity, finding a score of 20 or more may predict a more severe disease course.
Joint Venture: 2021 Updates in Rheumatoid Arthritis
An update on the state of RA management was presented by Dr. Bryant England, a co-author of the 2021 ACR Guideline on the Management of Rheumatoid Arthrits, during the Review Course held during ACR Convergence 2021.
The Many Facets of COVID-19: Experts Address Basic & Clinical Research Concepts in the COVID-19 Era
New concepts in autoimmunity & immunology are being discovered daily in research being conducted to understand the SARS-CoV-2 virus and its implications for rheumatology & all fields of medicine. Here are some insights shared by experts during day 1 of the Basic and Clinical Research Conference.
- « Previous Page
- 1
- …
- 52
- 53
- 54
- 55
- 56
- …
- 317
- Next Page »